Cargando…

Risk of venous thromboembolism with janus kinase inhibitors in inflammatory immune diseases: a systematic review and meta-analysis

Objectives: This study aimed to evaluate the risk of venous thrombosis (VTE) associated with Janus kinase (JAK) inhibitors in patients diagnosed with immune-mediated inflammatory diseases. Methods: We conducted a comprehensive search of PUBMED, Cochrane, and Embase databases for randomized controlle...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Juqi, Li, Wenhui, Gong, Mingli, Gu, Yanlun, Zhang, Hanxu, Dong, Bingqi, Guo, Qi, Pang, Xiaocong, Xiang, Qian, He, Xu, Cui, Yimin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10282754/ https://www.ncbi.nlm.nih.gov/pubmed/37351513 http://dx.doi.org/10.3389/fphar.2023.1189389

Ejemplares similares

Identification of potential ferroptosis-associated biomarkers in rheumatoid arthritis
por: He, Xu, et al.
Publicado: (2023)

Targeting integrin pathways: mechanisms and advances in therapy
por: Pang, Xiaocong, et al.
Publicado: (2023)

A novel immunogenic cell death–related subtype classification and risk signature for predicting prognosis and immunotherapy efficacy in gastric cancer
por: Dong, Bingqi, et al.
Publicado: (2023)

Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: case presentation and literature review
por: Mori, Shunsuke, et al.
Publicado: (2021)

Cardiovascular and Venous Thromboembolic Risk With Janus Kinase Inhibitors in Immune‐Mediated Inflammatory Diseases: A Systematic Review and Meta‐Analysis of Randomized Trials
por: Maqsood, Muhammad Haisum, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Direct Oral Anticoagulants Versus Vitamin K Antagonists for Venous Thromboembolism in China
por: Sun, Ke-Xin, et al.
Publicado: (2021)

Cardiovascular safety of Janus kinase inhibitors in patients with rheumatoid arthritis: systematic review and network meta-analysis
por: Wei, Qige, et al.
Publicado: (2023)

Co-expression and prognosis analyses of GLUT1–4 and RB1 in breast cancer
por: Zhang, Xiaodan, et al.
Publicado: (2021)

Therapeutic implications of current Janus kinase inhibitors as anti-COVID agents: A review
por: Jain, Nem Kumar, et al.
Publicado: (2023)

Discovery of C19-9 as a novel non-RGD inhibitor of αvβ3 to overcome enzalutamide resistance in castration-resistant prostate cancer
por: Pang, Xiaocong, et al.
Publicado: (2023)

Analysis of Suspension of Clinical Trials for Drug Registration in China
por: Su, Xian, et al.
Publicado: (2021)

New Oral Anticoagulants for Venous Thromboembolism Prophylaxis in Total Hip and Knee Arthroplasty: A Systematic Review and Network Meta-Analysis
por: Yi, Yi-hu, et al.
Publicado: (2022)

Safety of Janus Kinase Inhibitors in Older Patients: A Focus on the Thromboembolic Risk
por: Rajasimhan, Suraj, et al.
Publicado: (2020)

Sulodexide for Secondary Prevention of Recurrent Venous Thromboembolism: A Systematic Review and Meta-Analysis
por: Jiang, Qing-Jun, et al.
Publicado: (2018)

Cost-effectiveness of janus kinase inhibitors for rheumatoid arthritis: A systematic review and meta-analysis of cost-utility studies
por: Kumar, S. Sajith, et al.
Publicado: (2022)

Voltage-Controlled Enzymes: The New Janus Bifrons
por: Villalba-Galea, Carlos A.
Publicado: (2012)

Population Pharmacokinetic Analysis of Dalteparin in Pediatric Patients With Venous Thromboembolism
por: Damle, Bharat, et al.
Publicado: (2020)

Contribution of Janus-Kinase/Signal Transduction Activator of Transcription Pathway in the Pathogenesis of Vasculitis: A Possible Treatment Target in the Upcoming Future
por: Bursi, Roberto, et al.
Publicado: (2021)

Characteristics and Predictors of Venous Thromboembolism Among Lymphoma Patients Undergoing Chemotherapy: A Cohort Study in China
por: Chen, Yue, et al.
Publicado: (2022)

Corrigendum: Voltage-controlled enzymes: the new Janus Bifrons
por: Villalba-Galea, Carlos A.
Publicado: (2015)

Potential Adverse Events Reported With the Janus Kinase Inhibitors Approved for the Treatment of Rheumatoid Arthritis Using Spontaneous Reports and Online Patient Reviews
por: Song, Yun-Kyoung, et al.
Publicado: (2022)

The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease
por: De Vries, L.C.S., et al.
Publicado: (2017)

Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases
por: Núñez, Paulina, et al.
Publicado: (2023)

Use of Enoxaparin to Counteract COVID-19 Infection and Reduce Thromboembolic Venous Complications: A Review of the Current Evidence
por: Drago, Filippo, et al.
Publicado: (2020)

Venous thromboembolism in inflammatory bowel disease
por: Cheng, Kimberly, et al.
Publicado: (2020)

The Janus kinases (Jaks)
por: Yamaoka, Kunihiro, et al.
Publicado: (2004)

Janus Kinases in Leukemia
por: Raivola, Juuli, et al.
Publicado: (2021)

Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants for Venous Thromboembolism Prophylaxis in Patients With Cancer: A Systematic Review and Trade-Off Analysis From 9 Randomized Controlled Trials
por: Yan, Yi-Dan, et al.
Publicado: (2018)

Risk of venous thromboembolism in Chinese pregnant women: Hong Kong venous thromboembolism study
por: Huang, Duo, et al.
Publicado: (2019)

SPP1 Promotes Enzalutamide Resistance and Epithelial-Mesenchymal-Transition Activation in Castration-Resistant Prostate Cancer via PI3K/AKT and ERK1/2 Pathways
por: Pang, Xiaocong, et al.
Publicado: (2021)

Clinical Pharmacology of Janus Kinase Inhibitors in Inflammatory Bowel Disease
por: Lefevre, Pavine L C, et al.
Publicado: (2020)

The Era of Janus Kinase Inhibitors for Inflammatory Bowel Disease Treatment
por: Kim, Jin-Woo, et al.
Publicado: (2021)

Molecular dissection of Janus kinases as drug targets for inflammatory diseases
por: Kwon, Sunghark
Publicado: (2022)

Antithrombotic therapy for secondary prevention of unprovoked venous thromboembolism: a systematic review and network meta-analysis of randomized controlled trials
por: Li, Dandan, et al.
Publicado: (2022)

Biotechnologically Produced Lavandula angustifolia Mill. Extract Rich in Rosmarinic Acid Resolves Psoriasis-Related Inflammation Through Janus Kinase/Signal Transducer and Activator of Transcription Signaling
por: Koycheva, Ivanka K., et al.
Publicado: (2021)

Cardiovascular risk of Janus kinase inhibitors compared with biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis without underlying cardiovascular diseases: a nationwide cohort study
por: Song, Yun-Kyoung, et al.
Publicado: (2023)

Itch and Janus Kinase Inhibitors
por: HAN, Yujin, et al.
Publicado: (2023)

Development of a risk assessment scale for perinatal venous thromboembolism in Chinese women using a Delphi-AHP approach
por: Zhang, Meng, et al.
Publicado: (2022)

Thromboembolic Adverse Drug Reactions in Janus Kinase (JAK) Inhibitors: Does the Inhibitor Specificity Play a Role?
por: Kotyla, Przemysław J., et al.
Publicado: (2021)

Janus Kinase inhibitors in the New Treatment Paradigms of Inflammatory Bowel Disease
por: Siegmund, Britta
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mg9cmuv6v6s0blp94i9ui097gr